Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; zaltenibart that is in phase 3 clinical trials for Paroxysmal nocturnal hemoglobinuria; in phase 2 clinical trial for the treatment complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Immunostimulator Combination Therapies, and Oncotoxins and Immunomodulators for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Market Cap	$813.23M	P/E Ratio	N/A
52W High	$13.60	52W Low	$2.95
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	-42.0%	52W Position	67.6%
Overall Score	52	Value Score	40
Quality Score	36	Technical Score	81

EPS Current Est	$-1.89	EPS Next Est	$-1.77
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	OMER	$10.15	-4.15%	1.11M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	OMER	$10.15	-4.2%	1.11M
3
4
5
6

OMER

OMER

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Omeros Corporation Data in Excel

Get Omeros Corporation Data in Excel